Date: 2013-06-24
Type of information: Fundraising
Company: vasopharm (Germany)
Investors: HeidelbergCapital Private Equity and Entrepreneurs Fund (EF Investments S.à.r.l.) (Germany) Bayern Kapital (Germany) Hanseatic Asset Management LBG (Guernsey) Dr Andrew Clark, Chairman of the Board of vasopharm
Amount: €5 million
Funding type: series F financing round
Planned used: The proceeds of this round will be used primarily for the preparation of a Phase III clinical study of the company’s lead compound VAS203, an allosteric nitric oxide synthase inhibitor under development for the treatment of traumatic brain injury (TBI)
Others: * On June 24, 2013, vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebro- and cardiovascular diseases, has announced the successful completion of a Series F financing round totalling €5 million (~ US$6.5 million). The round was led by existing investors HeidelbergCapital Private Equity and Entrepreneurs Fund (EF Investments S.à.r.l.). Bayern Kapital, another existing investor, also participated in the Series F round. The consortium was joined by new investors Hanseatic Asset Management LBG and Dr Andrew Clark, Chairman of the Board of vasopharm. The new consortium also acquired the shares of one of the founding investors seeking to exit.
The proceeds of this round will be used primarily for the preparation of a Phase III clinical study of the company’s lead compound VAS203, an allosteric nitric oxide synthase inhibitor under development for the treatment of traumatic brain injury (TBI). The compound has met all clinical endpoints for safety and demonstrated strong evidence of clinical benefit in the Phase IIa European NOSTRA trial completed in 2012. Detailed results of the trial will be published soon in a peer-reviewed journal.
Therapeutic area: CNS diseases
